Moody’s upgrades Agnico Eagle’s rating to A3 on debt reduction
FORT WORTH, TX— Lantern Pharma Inc . (NASDAQ:LTRN), a biotech company with a market capitalization of $34.8 million, has seen significant activity from its major shareholders, as reported in the latest SEC Form 4 filing dated June 10, 2025. The filing details a series of transactions involving the sale of common stock by entities associated with Leslie W. Kreis and Cavu Management, LP. According to InvestingPro data, the stock has experienced considerable volatility, with shares down over 40% in the past year.
Over the course of three days, from June 10 to June 12, a total of $208,271 worth of Lantern Pharma stock was sold. The shares were sold at prices ranging from $3.38 to $3.40 per share, with the stock currently trading at $3.23. The transactions were conducted by various funds under the umbrella of Bios Equity Partners, including Bios Fund I, LP, Bios Fund I QP, LP, Bios Fund II NT, LP, Bios Fund II QP, LP, and Bios Fund II, LP.
These moves come as part of a broader strategy by the reporting entities, which are managed and controlled by Leslie W. Kreis and Aaron Glenn Louis Fletcher. Both Kreis and Fletcher have shared voting and investment control over the shares held by the associated funds.
The transactions reflect ongoing portfolio management by these significant shareholders, who continue to hold substantial positions in Lantern Pharma following the sales.
In other recent news, Lantern Pharma Inc. reported a narrower net loss for the first quarter of 2025, highlighting its strategic focus on cost management and innovation in drug development. The company’s net loss decreased to $4.5 million, or $0.42 per share, compared to $5.4 million in the same period last year. Lantern Pharma maintains a strong cash position of $19.7 million, which is expected to support operations through May 2026. The company has made significant progress in its clinical trials, particularly with its drug candidate LP-184, which has shown promise in treating a rare pediatric brain cancer. Lantern Pharma is also advancing its AI-driven drug discovery platform, RADAR, which continues to enhance its competitive edge in precision oncology. The company is preparing for a pediatric Phase I trial for LP-184 in brain tumors, following ongoing trials in adult solid tumors. Additionally, Lantern Pharma’s AI platform is set to expand, with plans to commercialize initial modules, potentially opening new revenue streams and fostering collaborations. These developments reflect Lantern Pharma’s ongoing efforts to leverage AI and machine learning to accelerate oncology drug development.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.